Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Modinos

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Psychological Medicine|December 5, 2017
Neuroanatomical changes in people with high schizotypy: relationship to glutamate levelsGemma Modinos, Alice Egerton, Anna McLaughlin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2006
A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's diseaseL Tárraga, M Boada, G Modinos, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2023
Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for PsychosisNicholas R Livingston, Andrea De Micheli, Robert McCutcheon, et al.
Schizophrenia Bulletin|April 3, 2024
Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for PsychosisNicholas R Livingston, Andrea De Micheli, Robert A McCutcheon, et al.
Journal of Clinical and Experimental Neuropsychology|January 15, 2009
Detection of visuoperceptual deficits in preclinical and mild Alzheimer's diseaseMontse Alegret, Mercè Boada-Rovira, Georgina Vinyes-Junqué, et al.
JAMA Psychiatry|November 15, 2018
Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for PsychosisMatthijs G Bossong, Mathilde Antoniades, Matilda Azis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2021
GABA<sub>A</sub> and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophreniaAmanda Kiemes, Felipe V Gomes, Diana Cash, et al.
Translational Psychiatry|November 11, 2021
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2019
Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging studyOliver D Howes, Ilaria Bonoldi, Robert A McCutcheon, et al.
Psychological Medicine|July 29, 2014
Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high riskG Modinos, P Allen, M Frascarelli, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Psychological Medicine|December 5, 2017
Neuroanatomical changes in people with high schizotypy: relationship to glutamate levelsGemma Modinos, Alice Egerton, Anna McLaughlin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2006
A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's diseaseL Tárraga, M Boada, G Modinos, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2023
Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for PsychosisNicholas R Livingston, Andrea De Micheli, Robert McCutcheon, et al.
Schizophrenia Bulletin|April 3, 2024
Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for PsychosisNicholas R Livingston, Andrea De Micheli, Robert A McCutcheon, et al.
Journal of Clinical and Experimental Neuropsychology|January 15, 2009
Detection of visuoperceptual deficits in preclinical and mild Alzheimer's diseaseMontse Alegret, Mercè Boada-Rovira, Georgina Vinyes-Junqué, et al.
JAMA Psychiatry|November 15, 2018
Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for PsychosisMatthijs G Bossong, Mathilde Antoniades, Matilda Azis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2021
GABA<sub>A</sub> and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophreniaAmanda Kiemes, Felipe V Gomes, Diana Cash, et al.
Translational Psychiatry|November 11, 2021
Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic functionPaul Allen, Emily J Hird, Natasza Orlov, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2019
Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging studyOliver D Howes, Ilaria Bonoldi, Robert A McCutcheon, et al.
Psychological Medicine|July 29, 2014
Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high riskG Modinos, P Allen, M Frascarelli, et al.
Pageof 9